Publication: Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors
Issued Date
2017-01-01
Resource Type
ISSN
23146141
23146133
23146133
Other identifier(s)
2-s2.0-85014274213
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BioMed Research International. Vol.2017, (2017)
Suggested Citation
Jeerunda Santiprabhob, Surapong Tanchaweng, Sirinoot Maturapat, Alan Maleesatharn, Watcharee Lermankul, Sirintip Sricharoenchai, Orasri Wittawatmongkol, Keswadee Lapphra, Wanatpreeya Phongsamart, Kulkanya Chokephaibulkit Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors. BioMed Research International. Vol.2017, (2017). doi:10.1155/2017/7481597 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/42030
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors
Other Contributor(s)
Abstract
© 2017 Jeerunda Santiprabhob et al. Protease inhibitor (PI) may cause abnormal glucose metabolism, abnormal lipid metabolism, and metabolic syndrome in HIV-infected adults but less well studied in Asian adolescents. This cross-sectional study evaluated anthropometric factors, oral glucose tolerance test, and lipid profiles of perinatally HIV-infected Thai adolescents who had received PI-based antiretroviral therapy for at least 6 months. Eighty adolescents were enrolled [median (IQR) age 16.7 (14.6-18.0) years, 42 males]. Metabolic syndrome, prediabetes, and type 2 diabetes mellitus (T2DM) were found in 8 (10%), 17 (22.1%), and 3 (3.8%) adolescents, respectively. Dyslipidemia was found in 56 (70%) adolescents, with hypertriglyceridemia being the most common type. In multivariate analysis, presence of lipohypertrophy (OR: 25.7, 95% CI: 3.2-202.8; p=0.002) and longer duration of PI use (OR: 1.04, 95% CI: 1.00-1.08; p=0.023) were associated with metabolic syndrome. Obesity (OR: 7.71, 95% CI: 1.36-43.7; p=0.021), presence of lipohypertrophy (OR: 62.9, 95% CI: 4.97-795.6; p=0.001), and exposure to stavudine for ≥6 months (OR: 8.18, 95% CI: 1.37-48.7; p=0.021) were associated with prediabetes/T2DM, while exposure to tenofovir for ≥6 months reduced the risk (OR: 0.17, 95% CI: 0.04-0.78; p=0.022). Metabolic disorders were commonly found in adolescents receiving PI. Careful monitoring and early intervention to modify cardiovascular risk should be systematically implemented in this population particularly those with exposure to stavudine.